 |
245 Diseases |  |
372 Trials |
|
372 Trials |  |
11177 News |  |
| 12345678910111213...141142» |
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Rectal squamous cell carcinoma treated with neoadjuvant fluorouracil, oxaliplatin, cetuximab, and radiation: A case report of pathological complete response. (Pubmed Central) - Jun 21, 2024
This case firstly highlights the usefulness of SOX plus cetuximab combined with radiation in the treatment of locally advanced rSCC. However, a large-scale study is required to establish safe and effective treatment regimens.
- || cisplatin / Generic mfg.
Retrospective data, Review, Journal: Weekly Versus Bolus Cisplatin Concurrent With Definitive Radiation Therapy for Squamous Carcinoma of the Head and Neck: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Jun 18, 2024
However, a large-scale study is required to establish safe and effective treatment regimens. The cetuximab trials provide indirect data suggesting that the differences between cisplatin schedules are subtle.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer. (Pubmed Central) - Jun 18, 2024
Therefore, presentation of AREG on Rab11a-exosomes affects its ability to compete with cetuximab. We propose that this Rab11a-exosome-mediated mechanism contributes to the establishment of resistance in cetuximab-sensitive cells and may explain why in cetuximab-resistant tumours only some cells carry mutant KRAS.
- | Avastin (bevacizumab) / Roche
Journal, Surgery, Metastases: Explanatory Role of Conversion Surgery as a Mediator of the Mortality Risk Difference Between Patients With Unresectable Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR Agents Versus Bevacizumab. (Pubmed Central) - Jun 16, 2024
We propose that this Rab11a-exosome-mediated mechanism contributes to the establishment of resistance in cetuximab-sensitive cells and may explain why in cetuximab-resistant tumours only some cells carry mutant KRAS. Conversion surgery may account for the difference in survival outcomes between users of the anti-EGFR agents and bevacizumab.
- ||| P3 data, Review, Journal, Metastases: Anti?epidermal growth factor receptor monoclonal antibody therapy in locally advanced head and neck cancer: A systematic review of phase III clinical trials. (Pubmed Central) - Jun 14, 2024
Finally, three phase III trials tested the effectiveness of cetuximab plus RT in the treatment of human papillomavirus-positive oropharyngeal carcinoma, and found it to be inferior compared with cisplatin-RT in terms of OS, PFS and failure-free survival. Based on the aforementioned findings, it is difficult to conclude that anti-EGFR therapy in any form has an advantage over conventional chemoradiation in the treatment of LAHNSCC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal: BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab. (Pubmed Central) - Jun 13, 2024
The patient initially responded well, but his disease progressed 2 months later. Further research is needed to improve management strategies for BRAF V600E-mutated colorectal cancer with CNS metastases.
- | Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Verzenio (abemaciclib) / Eli Lilly
Journal: EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer. (Pubmed Central) - Jun 10, 2024
Likewise, patient-derived organoids (PDOs) from individuals with ER+ mBC, progressing on palbociclib, exhibited up-regulation of EGFR and HER2 pathways. In conclusion, our findings suggest that inhibiting EGFR and HER2 pathways might overcome resistance to ET+CDK4/6i in selected patients with ER+ mBC.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
P1 data, Journal, Metastases: A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer. (Pubmed Central) - Jun 9, 2024
Cetuximab plus cabozantinib demonstrated a manageable toxicity profile and preliminary efficacy in patients with heavily treated R/M HNSCC. The combination of cetuximab with MKIs targeting the AXL/MET/VEGFR axis warrants further investigation, including in cetuximab-na
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Development of a neopentyl 211At-labeled activated ester providing in vivo stable 211At-labeled antibodies for targeted alpha therapy. (Pubmed Central) - Jun 7, 2024
This 211At-activated ester demonstrated high reactivity, and enabled the completion of the reaction with the antibody within 10 min. In comparative biodistribution studies between 211At-labeled cetuximab and the corresponding 125I-labeled cetuximab in normal mice, both the thyroid and stomach showed radioactivity levels that were less than 1.0% of the injected dose.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial, Combination therapy, IO biomarker, Metastases: A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (clinicaltrials.gov) - Jun 6, 2024
P1, N=330, Not yet recruiting, Sponsor: Pfizer
- ||||| RMC-6236 / Revolution Medicines
New P1/2 trial: Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors (clinicaltrials.gov) - Jun 5, 2024
P1/2, N=406, Recruiting, Sponsor: Revolution Medicines, Inc.
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Tumor cell: Combining SiRP? decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells. (Pubmed Central) - Jun 3, 2024
Moreover, avelumab and cetuximab enhanced macrophage-mediated phagocytosis of tumor cells in vitro in the presence of CV1 and improved tumor control upon coadministration with A97L-T cells. Taken together, our study indicates important clinical promise for harnessing macrophages by combining CV1-coengineered TCR-T cells with targeted antibodies to direct phagocytosis against tumor cells.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data, Journal, Metastases: Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial. (Pubmed Central) - Jun 2, 2024
P2
Taken together, our study indicates important clinical promise for harnessing macrophages by combining CV1-coengineered TCR-T cells with targeted antibodies to direct phagocytosis against tumor cells. The study met its primary objectives on objective response and morbidity, and showed overall survival to be as good as in younger patients treated with standard regimens, indicating that the adapted EXTREME regimen could be used in older patients with recurrent or metastatic HNSCC who are deemed fit with use of a geriatric evaluation tool adapted to patients with head and neck cancer, such as the EGE.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, Metastases: Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program. (Pubmed Central) - Jun 2, 2024
The study met its primary objectives on objective response and morbidity, and showed overall survival to be as good as in younger patients treated with standard regimens, indicating that the adapted EXTREME regimen could be used in older patients with recurrent or metastatic HNSCC who are deemed fit with use of a geriatric evaluation tool adapted to patients with head and neck cancer, such as the EGE. The efficacy and safety of the BEACON triplet regimen in Japanese patients with BRAFV600E-mutant mCRC were consistent with those reported in the BEACON CRC trial, supporting its use as a standard treatment for pretreated patients with BRAFV600E-mutant mCRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Exosomal circPVT1 promotes angiogenesis in laryngeal cancer by activating the Rap1b-VEGFR2 signaling pathway. (Pubmed Central) - Jun 2, 2024
Furthermore, our xenograft models demonstrated that the combination of shRNA-circPVT1 and cetuximab showed high efficacy in inhibiting tumor growth and angiogenesis. Collectively, these findings uncover a novel mechanism of exosomal circular RNA-mediated angiogenesis modulation and provide a preclinical rationale for testing this analogous combination in patients with LC.
- | ganetespib (ADX-1612) / Aldeyra, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Combined treatment with cetuximab and STA9090 has synergistic anticancer effects on human non-small cell lung cancer. (Pubmed Central) - May 31, 2024
It is highly likely that these synergistic effects are mediated through RTK pathway inactivation caused by the combination. Therefore, our findings strongly and consistently support the potential synergistic effect of STA9090, an RTK inhibitor, in combination with EGFR-targeting agents.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Review, Journal: Revolutionizing non-melanoma skin cancer treatment: Receptor tyrosine kinase inhibitors take the stage. (Pubmed Central) - May 30, 2024
Other RTKIs were only employed in experimental investigations. Research indicates that RTKIs could potentially serve as a suitable alternative for elderly patients who are unable to undergo chemotherapy and radiotherapy.
- | Rexulti (brexpiprazole) / Lundbeck, Otsuka
Journal: Brexpiprazole Prevents the Malignant Progression of Human Colorectal Cancer Cells and Increases Its Sensitivity to EGFR Inhibition. (Pubmed Central) - May 30, 2024
Research indicates that RTKIs could potentially serve as a suitable alternative for elderly patients who are unable to undergo chemotherapy and radiotherapy. Our finding suggested that brexpiprazole inhibits proliferation, promotes apoptosis, and enhances CRC cells' sensitivity to cetuximab by regulating the EGFR pathway and it might be an efficacious treatment strategy for CRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Journal, Metastases: Gustave Roussy Immune Score (GRIm-Score) as a Prognostic and Predictive Score in Metastatic Colorectal Cancer. (Pubmed Central) - May 27, 2024
Integration of the GRIm-Score into clinical practice should be done with caution and is not recommended at this time. However, further research is needed to fully elucidate its clinical utility and optimize its incorporation into routine clinical care.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Loss of CDX1/CDX2 expression identifies cetuximab-resistant patients and offers novel therapeutic alternatives in metastatic colorectal cancer (Poster and Exhibition Hall) - May 26, 2024 - Abstract #EACR2024EACR_861;
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Modeling and treating cetuximab resistance using ex vivo colorectal tumor slices (Poster and Exhibition Hall) - May 26, 2024 - Abstract #EACR2024EACR_834;
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Litx (talaporfin) / Light Sciences Oncology
Preclinical, Journal: Cetuximab-Toxin Conjugate and NPe6 with Light Enhanced Cytotoxic Effects in Head and Neck Squamous Cell Carcinoma In Vitro. (Pubmed Central) - May 25, 2024
Our study is the first to report on the iTAP method using IT-Cmab and NPe6 for HNSCC. The cytotoxic effects are enhanced in cell lines with moderate levels of EGFR protein expression, but not in nonexpressing cell lines, which is expected to expand the range of therapeutic windows and potentially reduce complications.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Retrospective data, Review, Journal: Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy. (Pubmed Central) - May 24, 2024
However, further clinical trials are necessary to determine whether cetuximab + radiotherapy can replace cisplatin + radiotherapy for degraded treatment in individuals who meet the aforementioned characteristics, particularly those with platinum drug allergies. CRD42023445619.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
P1 data, Journal: Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies. (Pubmed Central) - May 23, 2024
P1
In conclusion, CAR-37 T-cells exhibited anti-tumor activity, with significant CAR expansion and cytokine production. CAR-37 T-cells may be an effective therapy in hematologic malignancies as a bridge to hematopoietic stem cell transplant.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Journal, Metastases: Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group. (Pubmed Central) - May 23, 2024
CAR-37 T-cells may be an effective therapy in hematologic malignancies as a bridge to hematopoietic stem cell transplant. In RAS/BRAF wt mCRC patients, an anti-EGFR rechallenge provides a feasible therapeutic option with clinical benefit (survival) and a manageable safety profile.
- || Cyramza (ramucirumab) / Eli Lilly, Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data, Journal: Combining anti-VEGFR and anti-EGFR antibodies: Randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer:(ECOG-ACRIN E7208). (Pubmed Central) - May 22, 2024
P2
Further phase 3 trials with appropriate patient-selection are required. (NCT01079780).
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Circulating tumor DNA, Metastases: Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - May 20, 2024
P1, N=36, Recruiting, Sponsor: University of Chicago
(NCT01079780). Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS
Comparing Head & Neck Cancer patient clinical response to treatment with response of Head & Neck Cancer tissue maintained on a microfluidic device. (Mezzanine level of the exhibition area) - May 17, 2024 - Abstract #BAHNO2024BAHNO_50;
- Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS
Clinical outcomes of advanced head and neck cancer patients treated with immune checkpoint inhibitors at Mount Vernon Cancer Centre (Mezzanine level of the exhibition area) - May 17, 2024 - Abstract #BAHNO2024BAHNO_44;
This study showed an overall survival (OS) benefit versus the standard EXTREME cetuximab-chemotherapy combination...The nivolumab cohort had a median PFS of 3.7m (0.7-55.3), with IRT in 41.5%, (n= 17)...Our analysis shows a similar safety profile and patient outcomes to a recent pooled analysis on use of pembrolizumab monotherapy and previously published immune checkpoint inhibitor studies. Pfs pembro data- table.png
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Patient reported outcome measures of head and neck cancer patients treated with curative intent radiotherapy within the Head and Neck 5000 cohort (Auditorium) - May 17, 2024 - Abstract #BAHNO2024BAHNO_15;
Our work suggests that PS, rather than age alone, is a better prognostic indicator for severity of acute and late effects. Logistic regression analysis is planned to assess for confounding variables, e.g. TNM stage, chemotherapy, cetuximab and smoking status.
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Retrospective data, Journal, Monotherapy, Metastases: Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study. (Pubmed Central) - May 17, 2024
Previous therapy with fruquintinib or regorafenib was allowed but not mandatory...Multivariate Cox regression analysis demonstrated that undergoing therapy after TAS-102 either with or without BEV was an independent risk factor for OS [hazard ratio (HR) =0.25; 95% confidence interval (CI): 0.09-0.71, P<0.01], and previous treatment with cetuximab was an independent protective factor for PFS (HR =0.17; 95% CI: 0.03-0.91, P=0.04)...There was a trend in favor of the combination of BEV plus TAS-102 regarding OS and DCR, without reaching statistical significance, and it means that there was no clear advantage of one over the other in terms of efficacy. Further prospective studies are still necessary to draw a definite conclusion.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, PD(L)-1 Biomarker, IO biomarker: The involvement of epidermal growth factor receptor/protein kinase B (Pubmed Central) - May 15, 2024
Further prospective studies are still necessary to draw a definite conclusion. OSCC cells-expressing PD-L1 induced by EGF stimulation may promote malignancy intrinsically via the activation of the EGFR/AKT signaling cascade.
- | utomilumab (PF-05082566) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 15, 2024
P1, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
OSCC cells-expressing PD-L1 induced by EGF stimulation may promote malignancy intrinsically via the activation of the EGFR/AKT signaling cascade. Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: SOX18 meditates the resistance of Bmi1-expressing cells to cetuximab in HNSCC. (Pubmed Central) - May 13, 2024
Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026 Taken together, the findings of our study suggest that Sox18 mediates the resistance of Bmi1-expressing cells to cetuximab in HNSCC via the oxidative phosphorylation pathway.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Memory-like differentiation enhances NK cell responses against colorectal cancer. (Pubmed Central) - May 13, 2024
ML NK cells from healthy donors and mCRC patients exhibited increased anti-CRC responses. Collectively, our findings demonstrate that ML NK cells exhibit enhanced responses against CRC targets, warranting further investigation in clinical trials for mCRC patients, including those who have failed ICB.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Metastases: Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important? (Pubmed Central) - May 11, 2024
Collectively, our findings demonstrate that ML NK cells exhibit enhanced responses against CRC targets, warranting further investigation in clinical trials for mCRC patients, including those who have failed ICB. No abstract available
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Gallic Acid Can Promote Low-Density Lipoprotein Uptake in HepG2 Cells via Increasing Low-Density Lipoprotein Receptor Accumulation. (Pubmed Central) - May 11, 2024
When the pathway was inhibited by EGFR mab cetuximab, it was observed that the activation of the EGFR-ERK1/2 signaling pathway induced by GA was also blocked...This ultimately results in increased LDLR protein accumulation and enhanced uptake of LDL in cells. In summary, the present study revealed the potential mechanism of GA's role in ameliorating NAFLD, with a view of providing a theoretical basis for the dietary supplementation of GA.
- | Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Programmed Death Ligand-1 and Tumor Burden Score Dictate Treatment Responses in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - May 11, 2024
Tumor burden is significantly correlated with survival in patients with R/M HNSCC. PD-L1 and TBS should be taken into consideration to determine first-line treatment.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. (Pubmed Central) - May 10, 2024
P2
Despite achieving an enhanced DpR, this improvement did not translate into improved R0 resection rates or PFS. Moreover, the triplet arm was associated with an increase in treatment-related toxicity.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Metastases: Safety and efficacy of neoadjuvant chemotherapy with paclitaxel, carboplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma. (Pubmed Central) - May 10, 2024
Moreover, the triplet arm was associated with an increase in treatment-related toxicity. NAC using the PCE regimen for patients with locally advanced HNSCC, including cisplatin-ineligible patients, has acceptable toxicity and favorable efficacy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: The Invasion Factor ODZ1 Is Upregulated through an Epidermal Growth Factor Receptor-Induced Pathway in Primary Glioblastoma Cells. (Pubmed Central) - May 10, 2024
MAPK, to upregulate the invasion factor ODZ1, which may initiate morphological changes for tumor cells to invade the surrounding parenchyma. These data identify a new candidate of the EGF-EGFR pathway for novel therapeutic approaches.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Statistical Analysis of Side Effects in Head and Neck Cancer Patients from ARTSCAN III trial (Hall 1) - May 8, 2024 - Abstract #ESTRO2024ESRTO_108;
The ElasticNet model outperformed the traditional Logistic Regression in predicting late xerostomia in terms of AUC. Our analysis showed that several dose volumes and other features correlated with xerostomia in contrast to clinical norm that focus on the mean dose.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
NG11-2 Phase Ib trial to reduce radiation-induced oral mucositis on patients with head & neck cancer (Forth) - May 8, 2024 - Abstract #ESTRO2024ESRTO_7;
This current study provides safety and preliminary efficacy evidence so far to support the decision on the RP2D. After the dose escalation, a final expansion phase will be carried out at the selected RP2D level to supply additional insight into the characteristics of HNC patient cohorts and the pharmaceutical effect of NG11-2.
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Combination therapy, Monotherapy, Metastases: EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer (clinicaltrials.gov) - May 8, 2024
P2, N=130, Active, not recruiting, Sponsor: University College, London
After the dose escalation, a final expansion phase will be carried out at the selected RP2D level to supply additional insight into the characteristics of HNC patient cohorts and the pharmaceutical effect of NG11-2. Trial completion date: Oct 2023 --> Oct 2024
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Preclinical, Review, Journal: Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road. (Pubmed Central) - May 7, 2024
However, alternative mechanisms underpinning resistance beyond genomics -mainly related to the tumor microenvironment-have been unveiled, specifically relevant in patients receiving chemotherapy-based multi-drug treatment in first line. This review explores the complexity of the multifaceted mechanisms that mediate secondary resistance to anti-EGFR therapies and potential therapeutic strategies to circumvent acquired resistance.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Concurrent simultaneous integrated boost radiotherapy and cetuximab in head and neck squamous cell cancer patients: is it feasible in daily clinical practice? (Pubmed Central) - May 6, 2024
This review explores the complexity of the multifaceted mechanisms that mediate secondary resistance to anti-EGFR therapies and potential therapeutic strategies to circumvent acquired resistance. The concurrent bio-radiotherapy of Sib-Imrt and cetuximab is feasible in real-life daily clinical practice for LA-Hnscc patients unfit for platinum-based chemoradiotherapy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Journal: Maxillary Sinus NUT Carcinoma: A Case Report. (Pubmed Central) - May 6, 2024
Effective treatments for NUT carcinoma have not yet been established. However, early testing to establish the diagnosis may provide useful insights to guide clinical decisions to improve patient outcomes.
- || BND-22 / Biond Biologics, Sanofi
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 3, 2024
P1/2, N=456, Recruiting, Sponsor: Sanofi
However, early testing to establish the diagnosis may provide useful insights to guide clinical decisions to improve patient outcomes. Trial completion date: Nov 2026 --> Feb 2027 | Trial primary completion date: Nov 2026 --> Feb 2027
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Hyaluronic acid-oleylamine and chitosan-oleic acid conjugate-based hybrid nanoparticle delivery via. dissolving microneedles for enhanced treatment efficacy in localized breast cancer. (Pubmed Central) - May 2, 2024
However, the HA-OA/CS-OA NPT-MN showed the highest tumor reduction and survival rate, with the lowest body weight reduction in comparison to other treatment groups, indicating its superior efficacy and low systemic toxicity. Overall, the dissolving microneedle-mediated delivery of targeted nanoparticles loaded with chemotherapeutics offers a superior alternative to conventional intravenous chemotherapy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, Real-world evidence, Real-world, Metastases: Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset. (Pubmed Central) - May 2, 2024
Our real-world data suggest that TT should be initiated as soon as possible after the failure of first-line treatment in BRAFV600E-mutated mCRC. Among patients with pMMR/MSS tumors, combinatory chemotherapy